| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BU Stock Overview
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada.
Burcon NutraScience Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.50 |
| 52 Week High | CA$3.85 |
| 52 Week Low | CA$0.50 |
| Beta | 2 |
| 1 Month Change | -43.18% |
| 3 Month Change | -57.63% |
| 1 Year Change | -86.49% |
| 3 Year Change | -28.57% |
| 5 Year Change | -63.77% |
| Change since IPO | -37.50% |
Recent News & Updates
Burcon NutraScience (TSE:BU) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| BU | CA Chemicals | CA Market | |
|---|---|---|---|
| 7D | -18.0% | -2.0% | -0.4% |
| 1Y | -86.5% | 38.7% | -2.9% |
Return vs Industry: BU underperformed the Canadian Chemicals industry which returned 38.1% over the past year.
Return vs Market: BU underperformed the Canadian Market which returned -2.6% over the past year.
Price Volatility
| BU volatility | |
|---|---|
| BU Average Weekly Movement | 10.3% |
| Chemicals Industry Average Movement | 12.9% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.3% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: BU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: BU's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 25 | Peter Kappel | https://www.burcon.ca |
Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. Its products include Peazazz, a pea protein for dairy alternative products, such as protein bars and crisps, weight management and meal replacement products, and vegetarian and vegan foods, as well as dry blended and ready-to-drink beverages; and Peazac, a pea protein for plant-based meat alternative products, ready-to-mix powders and beverages, dairy alternatives, nutrition bars, and other applications. The company also provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods.
Burcon NutraScience Fundamentals Summary
| BU fundamental statistics | |
|---|---|
| Market Cap | CA$54.36m |
| Earnings (TTM) | -CA$10.26m |
| Revenue (TTM) | CA$171.47k |
318.5x
P/S Ratio-5.3x
P/E RatioIs BU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BU income statement (TTM) | |
|---|---|
| Revenue | CA$171.47k |
| Cost of Revenue | CA$1.45m |
| Gross Profit | -CA$1.28m |
| Other Expenses | CA$8.98m |
| Earnings | -CA$10.26m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.094 |
| Gross Margin | -744.37% |
| Net Profit Margin | -5,982.59% |
| Debt/Equity Ratio | 0% |
How did BU perform over the long term?
See historical performance and comparisonValuation
Is BU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BU?
Other financial metrics that can be useful for relative valuation.
| What is BU's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CA$54.36m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 276.6x |
| Enterprise Value/EBITDA | -7.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does BU's PB Ratio compare to its peers?
| BU PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.2x | ||
CZO Ceapro | 1.6x | n/a | CA$46.7m |
VNP 5N Plus | 0.7x | 154.4% | CA$126.3m |
GGG G6 Materials | 1.4x | n/a | CA$11.5m |
NANO Nano One Materials | 5x | -10.3% | CA$251.5m |
BU Burcon NutraScience | 1.9x | 66.0% | CA$54.4m |
Price-To-Book vs Peers: BU is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (2.2x).
Price to Earnings Ratio vs Industry
How does BU's PE Ratio compare vs other companies in the CA Chemicals Industry?
Price-To-Book vs Industry: BU is good value based on its Price-To-Book Ratio (1.9x) compared to the Canadian Chemicals industry average (2.2x)
Price to Book Ratio vs Fair Ratio
What is BU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate BU's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BU (CA$0.5) is trading below our estimate of fair value (CA$1.39)
Significantly Below Fair Value: BU is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BU's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Burcon NutraScience forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BU's revenue (43.3% per year) is forecast to grow faster than the Canadian market (7% per year).
High Growth Revenue: BU's revenue (43.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BU's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Burcon NutraScience performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
1.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BU is currently unprofitable.
Growing Profit Margin: BU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BU is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BU is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (30.2%).
Return on Equity
High ROE: BU has a negative Return on Equity (-36.32%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Burcon NutraScience's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BU's short term assets (CA$7.6M) exceed its short term liabilities (CA$1.0M).
Long Term Liabilities: BU's short term assets (CA$7.6M) exceed its long term liabilities (CA$58.7K).
Debt to Equity History and Analysis
Debt Level: BU is debt free.
Reducing Debt: BU has no debt compared to 5 years ago when its debt to equity ratio was 44.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BU has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 3.1% each year.
Discover healthy companies
Dividend
What is Burcon NutraScience current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BU has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
12.8yrs
Average management tenure
CEO
Peter Kappel
0.25
Tenure
CA$298,755
Compensation
Mr. Peter H. Kappel had been Independent Director of Burcon Nutrascience Corporation since January 28, 2016 and serves as its Chairman since September 2021 and also serves as its Interim Chief executive Of...
Leadership Team
Experienced Management: BU's management team is seasoned and experienced (12.8 years average tenure).
Board Members
Experienced Board: BU's board of directors are considered experienced (8.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Burcon NutraScience Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Burcon NutraScience Corporation
- Ticker: BU
- Exchange: TSX
- Founded: 1998
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: CA$54.364m
- Shares outstanding: 108.73m
- Website: https://www.burcon.ca
Number of Employees
Location
- Burcon NutraScience Corporation
- 1946 West Broadway
- Vancouver
- British Columbia
- V6J 1Z2
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/28 00:00 |
| End of Day Share Price | 2022/06/28 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2022/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.